Merck (MRK) Shares Up Significantly Since Jim Cramer Advised to “Stay the Course”

Group 1 - Merck & Co., Inc. (NYSE:MRK) is entering the weight loss drug market with the HS-10535 drug, licensed from Hanosh Pharmaceutical through a $2 billion agreement [1] - The company's shares have increased by 33% over the past year and 46% since Jim Cramer discussed the firm on April 9th [1] - Merck's shares closed 3.8% higher on November 18th following positive data for its heart drug Winrevair, and the stock is up 12.4% year-to-date [1] Group 2 - In the fiscal fourth quarter, Merck reported $16.4 billion in revenue and $2.04 in adjusted profit per share, surpassing analyst estimates of $16.2 billion and $2.01 [1] - The company projected revenue between $65.5 billion and $67 billion, which is below analyst expectations, citing loss of exclusivity for several medicines as a significant factor [1] - Jim Cramer advised investors to hold onto their Merck shares, acknowledging the stock's poor performance but suggesting a potential for recovery at a 4% yield [1]